# US 2008/0305075 A1 · Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide and Analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305075 A1
- Document ID: US20080305075A1
- Status: Published application
- Kind: A1
- Application number: 12/111,672
- Filed: 2008-04-29
- Published: 2008-12-11
- Earliest claimed: 2006-02-17
- Assignees: Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon
- Inventors: John G. Curd; John F.W. Keana; Alshad S. Lalani; Paul B. Westberg; Bradford Goodwin; W. David Henner
- Web page: https://patentgrep.com/patent/US20080305075A1

## CPC

- C07D 519/04: Dimeric indole alkaloids, e.g. vincaleucoblastine
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.

## Claims

### Claim 1

A compound having formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R′1 represents hydrogen, alkyl, alkoxy, acyl, formyl or halogenoacyl group;
R′2 represents hydrogen or alkyl group;
R′3 and R″3 are identical or different and each independently represents hydrogen, hydroxy or alkanoyloxy group, or else R′3 and R″3 together form a carbonyl group or else R′3 and R′5 together form an epoxy bridge or a double bond;
R′4 represents hydrogen, alkyloxycarbonyl, hydroxymethyl or alkanoyloxymethyl group;
R′5 and R″5 are identical or different and each independently represents hydrogen, hydroxy, alkoxycarbonyl, C1-C7 alkyl optionally substituted with 1-3 halogen atoms, alkanoyloxy, or 2-hydroxyethyl group;
R′6 represents hydrogen, ethyl, 2-hydroxyethyl or acetyl group;
R′7 represents hydrogen or cyano;
R1 represents hydrogen, alkyl, formyl or acyl group;
R2 represents hydrogen or alkoxy;
R3 represents hydrogen, hydroxy or alkanoyloxyl group, or else R3 and R4 together form an epoxy bridge or a double bond;
R4 represents hydrogen, hydroxy or alkanoyloxy group, or else R4 and R5 together form an epoxy bridge;
R6 represents an alkyloxycarbonyl, hydrazido, acetamido, hydroxymethyl, alkanoyloxymethyl group or —C(═O)-A-NH—P, where -A- is one of —NH—, —NH-alk-COO— or —NH-alk-COONH—, alk is a straight chain or branched C1-C7 alkyl group and —NH—P is a peptide residue, or R5 and R6 together form an oxazolidine-2,4-dione ring;
R5 and R7 represent hydrogen, hydroxy or alkanoyloxy group, as well as their addition salts with acids and their quaternary ammonium salts;
each of R8 and R′8 is 0 or is absent provided that at least one of R8 and R′8 is 0; and
n is 1 or 2;
with the proviso that the compound of Formula I is not vinorelbine N′b-oxide or vinblastine N′b-oxide.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound of Formula I is selected from the group consisting of desacetyl vinblastine N-oxide, vincristine N-oxide, desacetyl vinflunine N-oxide, desacetyl vinorelbine N-oxide, vindosine N-oxide and vinflunine N-oxide or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 3 (depends on 1)

The compound of claim 1, which is vincristine N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

The compound of claim 3, which is the dihydrochloride salt.

### Claim 5 (depends on 1)

The compound of claim 1, which is vinblastine N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5, which is the dihydrochloride salt.

### Claim 7 (depends on 1)

The compound of claim 1, which is vinflunine N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The compound of claim 7, which is the dihydrochloride salt.

### Claim 9 (depends on 1)

A metronomic dosing regime for a compound of claim 1 comprising repeatedly administering a compound of formula I at a dose below the maximum tolerated dose.

### Claim 10

A method of treating, ameliorating, or preventing a hyperproliferative disorder comprising administering to an animal in need thereof a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R′1 represents hydrogen, alkyl, alkoxy, acyl, formyl or halogenoacyl group;
R′2 represents hydrogen or alkyl group;
R′3 and R″3 are identical or different and each independently represents hydrogen, hydroxy or alkanoyloxy group, or else R′3 and R″3 together form a carbonyl group or else R′3 and R′5 together form an epoxy bridge or a double bond;
R′4 represents hydrogen, alkyloxycarbonyl, hydroxymethyl or alkanoyloxymethyl group;
R′5 and R″5 are identical or different and each independently represents hydrogen, hydroxy, alkoxycarbonyl, C1-C7 alkyl optionally substituted with 1-3 halogen atoms, alkanoyloxy, or 2-hydroxyethyl group;
R′6 represents hydrogen, ethyl, 2-hydroxyethyl or acetyl group;
R′7 represents hydrogen or cyano;
R1 represents hydrogen, alkyl, formyl or acyl group,
R2 represents hydrogen or alkoxy;
R3 represents hydrogen, hydroxy or alkanoyloxy group, or else R3 and R4 together form an epoxy bridge or a double bond;
R4 represents hydrogen, hydroxy or alkanoyloxy group, or else R4 and R5 together form an epoxy bridge;
R6 represents an alkyloxycarbonyl, hydrazido, acetamido, hydroxymethyl, alkanoyloxymethyl group or —C(═O)-A-NH—P, where -A- is one of —NH—, —NH-alk-COO— or —NH-alk-COONH—, alk is a straight chain or branched C1-C7 alkyl group and —NH—P is a peptide residue, or R5 and R6 together form an oxazolidine-2,4-dione ring;
R5 and R7 represent hydrogen, hydroxy or alkanoyloxy group, as well as their addition salts with acids and their quaternary ammonium salts;
each of R8 and R′8 is 0 or is absent provided that at least one of R8 and R18 is 0; and
n is 1 or 2.

### Claim 11 (depends on 1)

A method of treating, preventing or ameliorating a hyperproliferative disorder in an animal in need thereof, comprising
(a) determining whether said hyperproliferative disorder is characterized by hypoxic tissue, and
(b) treating said animal with an effective amount of a compound of claim 1.

### Claim 12 (depends on 10, 11)

The method of claim 10 or 11, wherein said compound of Formula I is selected from the group consisting of vinblastine N-oxide, desacetyl vinblastine N-oxide, vinorelbine N-oxide, vincristine N-oxide, desacetyl vinflunine N-oxide, desacetyl vinorelbine N-oxide, vindosine N-oxide and vinflunine N-oxide or a pharmaceutically acceptable salt or prodrug or diastereomer thereof.

### Claim 13 (depends on 10, 11)

The method of claim 10 or 11, which is vincristine N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The method of claim 13, which is the dihydrochloride salt.

### Claim 15 (depends on 10, 11)

The method of claim 10 or 11, which is vinblastine N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, which is the dihydrochloride salt.

### Claim 17 (depends on 10)

The method of claim 10, further comprising subjecting said animal to an imaging technique selected from the group consisting of computed tomography, magnetic resonance imaging, single photon emission computer tomography and positron emission tomography prior to or during administration of said compound.

### Claim 18 (depends on 10, 11)

The method of claim 10 or 11, further comprising administering to said animal a topoisomerase 1 inhibitor.

### Claim 19 (depends on 18)

The method of claim 18 wherein said topoisomerase 1 inhibitor is selected from the group consisting of topotecan, irinotecan, 9-aminocamptothecin, 10-aminocamptothecin, 10,11-methylenedioxycamptothecin and SN-38, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein said compound of Formula I is selected from the group consisting of vinblastine N-oxide, desacetyl vinblastine N-oxide, vinorelbine N-oxide, vincristine N-oxide, desacetyl vinflunine N-oxide, desacetyl vinorelbine N-oxide, vindosine N-oxide and vinflunine N-oxide or a pharmaceutically acceptable salt or prodrug or diastereomer thereof.

### Claim 21 (depends on 20)

The method claim 20, wherein said topoisomerase 1 inhibitor is irinotecan, or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein irinotecan, or a pharmaceutically acceptable salt thereof, is administered 50 mg/m2 to 500 mg/m2 once weekly, once every two weeks or once every three weeks.

### Claim 23 (depends on 21)

The method of claim 21, wherein the compound of Formula I is vinblastine N-oxide or vincristine N-oxide.

### Claim 24 (depends on 23)

The method of claim 23, wherein the compound of Formula I is administered 1 mg/kg q3d×5 to 500 mg/kg q3d×5.

### Claim 25 (depends on 24)

The method of claim 24, wherein the compound of Formula I is administered 5 mg/kg q3d×5 to 50 mg/kg q3d×5.

### Claim 26 (depends on 10, 11)

The method of claim 10 or 11, wherein said hyperproliferative disorder is cancer.

### Claim 27 (depends on 26)

The method of claim 26, wherein the cancer is of the bladder, brain, breast, cervix, colon, endometrium, esophagus, head and neck, kidney, larynx, liver, lung, oral cavity, ovaries, pancreas, prostate, skin, stomach, or testis.

### Claim 28 (depends on 26)

The method of claim 26, wherein the cancer is selected from the group consisting of acute and chronic lymphocytic leukemia, acute granulocytic leukemia, adrenal cortex carcinoma, bladder carcinoma, breast carcinoma, cervical carcinoma, cervical hyperplasia, choriocarcinoma, chronic granulocytic leukemia, chronic lymphocytic leukemia, colon carcinoma, endometrial carcinoma, esophageal carcinoma, essential thrombocytosis, genitourinary carcinoma, hairy cell leukemia, head and neck carcinoma, Hodgkin's disease, Kaposi's sarcoma, lung carcinoma, lymphoma, malignant carcinoid carcinoma, malignant hypercalcemia, malignant melanoma, malignant pancreatic insulinoma, medullary thyroid carcinoma, melanoma, multiple myeloma, mycosis fungoides, myeloid and lymphocytic leukemia, neuroblastoma, non-Hodgkin's lymphoma, osteogenic sarcoma, ovarian carcinoma, pancreatic carcinoma, polycythemia vera, primary brain carcinoma, primary macroglobulinemia, prostatic carcinoma, renal cell carcinoma, rhabdomyosarcoma, skin cancer, small-cell lung carcinoma, soft-tissue sarcoma, squamous cell carcinoma, stomach carcinoma, testicular carcinoma, thyroid carcinoma, and Wilms' tumor.

### Claim 29 (depends on 10, 11)

The method of claim 10 or 11, wherein said hyperproliferative disorder is age-related macular degeneration, Crohn's disease, cirrhosis, chronic inflammatory-related disorders, diabetic retinopathy, granulomatosis, immune hyperproliferation associated with organ or tissue transplantation, an immunoproliferative disease or disorder, e.g., inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, vascular hyperproliferation secondary to retinal hypoxia, or vasculitis.

### Claim 30 (depends on 10, 11)

The method of claim 10 or 11, further comprising administering one or more other active agents or treatments to the animal.

### Claim 31 (depends on 30)

The method of claim 30, wherein said one or more other active agents or treatments are independently selected from the group consisting of a chemotherapeutic agent, a radiotherapeutic agent/treatment, an anti-angiogenesis agent, a vascular targeting agent, an HIF1 inhibitor, an Hsp90 inhibitor, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, a proteasome inhibitor, an HDAC inhibitor, a caspase inducer, a CDK inhibitor, and a proapoptotic molecule.

### Claim 32 (depends on 31)

The method of claim 31, wherein the chemotherapeutic agent is selected from the group consisting of abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrozole, arsenic trioxide, asparaginase, BCG live, bevaceizumab, bexarotene, bleomycin, bortezomib, busulfan, calusterone, camptothecin, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cinacalcet, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone, Elliott's B solution, epirubicin, epoetin alfa, estramustine, etoposide, exemestane, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gemcitabine, gemtuzumab ozogamicin, gefitinib, goserelin, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, interferon alfa-2a, interferon alfa-2b, irinotecan, letrozole, leucovorin, levamisole, lomustine, meclorethamine, megestrol, melphalan, mercaptopurine, mesna, methotrexate, methoxsalen, methylprednisolone, mitomycin C, mitotane, mitoxantrone, nandrolone, nofetumomab, oblimersen, oprelvekin, oxaliplatin, paclitaxel, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed, pentostatin, pipobroman, plicamycin, polifeprosan, porfimer, procarbazine, quinacrine, rasburicase, rituximab, sargramostim, streptozocin, talc, tamoxifen, tarceva, temozolomide, teniposide, testolactone, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, and zoledronate.

### Claim 33 (depends on 31)

The method of claim 31, wherein said anti-angiogenesis agent is selected from the group consisting of bevacizumab, angiostatin, endostatin, batimastat, captopril, cartilage derived inhibitor, genistein, interleukin 12, lavendustin, medroxypregesterone acetate, recombinant human platelet factor 4, tecogalan, thrombospondin, TNP-470, anti-VEGF monoclonal antibody, soluble VEGF-receptor chimaeric protein, anti-VEGF receptor antibodies, anti-PDGF receptors, inhibitors of integrins, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, antisense oligonucleotides, antisense oligodexoynucleotides, siRNAs, anti-VEGF aptamers and pigment epithelium derived factor.

### Claim 34 (depends on 30)

The method of claim 30, wherein said compound is administered prior to the administration of said active agents or treatments.

### Claim 35 (depends on 30)

The method of claim 30, wherein said compound is administered concurrently with the administration of said active agents or treatments.

### Claim 36 (depends on 30)

The method of claim 30, wherein the administration of said compound is continued beyond the administration of said active agents or treatments.

### Claim 37 (depends on 30)

The method of claim 30, wherein said compound is administered after the administration of said active agents or treatments.

### Claim 38 (depends on 30)

The method of claim 30, wherein the method is repeated at least once.

### Claim 39

A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt or diastereomer thereof, wherein:
R′1 represents hydrogen, alkyl, alkoxy, acyl, formyl or halogenoacyl group;
R′2 represents hydrogen or alkyl group;
R′3 and R″3 are identical or different and each independently represents hydrogen, hydroxy or alkanoyloxy group, or else R′3 and R″3 together form a carbonyl group or else R′3 and R′5 together form an epoxy bridge or a double bond;
R′4 represents hydrogen, alkyloxycarbonyl, hydroxymethyl or alkanoyloxymethyl group;
R′5 and R″5 are identical or different and each independently represents hydrogen, hydroxy, alkoxycarbonyl, C1-C7 alkyl optionally substituted with 1-3 halogen atoms, alkanoyloxyl, or 2-hydroxyethyl group;
R′6 represents hydrogen, ethyl, 2-hydroxyethyl or acetyl group;
R′7 represents hydrogen or cyano;
R1 represents hydrogen, alkyl, formyl or acyl group,
R2 represents hydrogen or alkoxy;
R3 represents hydrogen, hydroxy or alkanoyloxy group, or else R3 and R4 together form an epoxy bridge or a double bond;
R4 represents hydrogen, hydroxy or alkanoyloxy group, or else R4 and R5 together form an epoxy bridge;
R6 represents an alkyloxycarbonyl, hydrazido, acetamido, hydroxymethyl, alkanoyloxymethyl group or —C(═O)-A-NH—P, where -A- is one of —NH—, —NH-alk-COO— or —NH-alk-COONH—, alk is a straight chain or branched C1-C7 alkyl group and —NH—P is a peptide residue, or R5 and R6 together form an oxazolidine-2,4-dione ring;
R5 and R7 represent hydrogen, hydroxy or alkanoyloxy group, as well as their addition salts with acids and their quaternary ammonium salts;
each of R8 and R′8 is O or is absent provided that at least one of R8 and R′8 is O; and
n is 1 or 2.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein said compound is selected from the group consisting of vinblastine N-oxide, desacetyl vinblastine N-oxide, vinorelbine N-oxide, vincristine N-oxide, desacetyl vinflunine N-oxide, desacetyl vinorelbine N-oxide, vindosine N-oxide and vinflunine N-oxide or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 41 (depends on 39)

The pharmaceutical composition of claim 39, further comprising a topoisomerase 1 inhibitor.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein said topoisomerase 1 inhibitor is selected from the group consisting of topotecan, irinotecan, 9-aminocamptothecin, 10-aminocamptothecin, 10,11-methylenedioxycamptothecin and SN-38.

### Claim 43 (depends on 42)

The pharmaceutical composition of claim 42, wherein said compound of Formula I is selected from the group consisting of vinblastine N-oxide, desacetyl vinblastine N-oxide, vinorelbine N-oxide, vincristine N-oxide, desacetyl vinflunine N-oxide, desacetyl vinorelbine N-oxide, vindosine N-oxide and vinflunine N-oxide or a pharmaceutically acceptable salt or prodrug or diastereomer thereof.

### Claim 44 (depends on 39)

The pharmaceutical composition of claim 39, which is vincristine N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 44)

The pharmaceutical composition of claim 44, which is the dihydrochloride salt.

### Claim 46 (depends on 39)

The pharmaceutical composition of claim 39, which is vinblastine N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 46)

The pharmaceutical composition of claim 46, which is the dihydrochloride salt.

### Claim 48 (depends on 43)

The pharmaceutical composition of claim 43, wherein the topoisomerase 1 inhibitor is irinotecan and the compound of formula I is vinblastine N-oxide or vincristine N-oxide.

### Claim 49 (depends on 39)

The pharmaceutical composition of claim 39, further comprising one or more active agents independently selected from the group consisting of chemotherapeutic agents, anti-angiogenesis agents, vascular targeting agents, HIF1 inhibitors, Hsp90 inhibitors, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, a proteasome inhibitor, an HDAC inhibitor, a caspase inducer, a CDK inhibitor, and a proapoptotic molecule.

### Claim 50 (depends on 49)

The pharmaceutical composition of claim 49, wherein said chemotherapeutic agent is selected from the group consisting of abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrozole, arsenic trioxide, asparaginase, BCG live, bevaceizumab, bexarotene, bleomycin, bortezomib, busulfan, calusterone, camptothecin, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cinacalcet, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone, Elliott's B solution, epirubicin, epoetin alfa, estramustine, etoposide, exemestane, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gemcitabine, gemtuzumab ozogamicin, gefitinib, goserelin, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, interferon alfa-2a, interferon alfa-2b, irinotecan, letrozole, leucovorin, levamisole, lomustine, meclorethamine, megestrol, melphalan, mercaptopurine, mesna, methotrexate, methoxsalen, methylprednisolone, mitomycin C, mitotane, mitoxantrone, nandrolone, nofetumomab, oblimersen, oprelvekin, oxaliplatin, paclitaxel, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed, pentostatin, pipobroman, plicamycin, polifeprosan, porfimer, procarbazine, quinacrine, rasburicase, rituximab, sargramostim, streptozocin, talc, tamoxifen, tarceva, temozolomide, teniposide, testolactone, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, and zoledronate.

### Claim 51 (depends on 49)

The pharmaceutical composition of claim 49, wherein said anti-angiogenesis agent is selected from the group consisting of bevacizumab, angiostatin, endostatin, batimastat, captopril, cartilage derived inhibitor, genistein, interleukin 12, lavendustin, medroxypregesterone acetate, recombinant human platelet factor 4, tecogalan, thrombospondin, TNP-470, anti-VEGF monoclonal antibody, soluble VEGF-receptor chimaeric protein, anti-VEGF receptor antibodies, anti-PDGF receptors, inhibitors of integrins, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, antisense oligonucleotides, antisense oligodexoynucleotides, siRNAs, anti-VEGF aptamers and pigment epithelium derived factor.
